2026 Sol J. Barer Award Honoree Dr. Jan van de Winkel
2026 Sol J. Barer Award Honoree Dr. Jan van de Winkel.
President & Chief Executive Officer, Genmab
Search every verified Jan van de Winkel interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a 2023 interview, Jan van de Winkel discussed Genmab's operations and culture. He stated that during the COVID-19 pandemic, the company arranged for taxi services to transport laboratory employees to work individually to ensure continued operations. Van de Winkel described Genmab's approach as encouraging employees to take calculated risks and think unconventionally, while remaining focused on antibody-based medicines. He also acknowledged that some programs the company pursued had to be closed because they did not prove to be the right approach. In a 2016 interview, van de Winkel discussed Genmab's lead monoclonal antibody daratumumab, describing it as a unique molecule that uses multiple mechanisms to kill cancer cells. He noted that the drug showed potential as a treatment for multiple myeloma and relapsing-remitting multiple sclerosis, and mentioned that a subcutaneous formulation for autoimmune diseases was being developed by a partner. Van de Winkel expressed confidence that Genmab could innovate the commercial side of cancer drugs by holding onto product ownership for smaller markets.
2026 Sol J. Barer Award Honoree Dr. Jan van de Winkel.
02/14/2024 Q&A: 37:49 Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotum…
Genmab is misschien wel het best bewaarde geheim van de regio Utrecht. Maar intussen wel het op één na grootste biotechnologie bedrijf in Europa met een marktkapitalisatie van rond de 25 miljard Euro. Genmab is een internationaal biotechnologiebedrijf dat antilichaamgeneesmiddelen ontwikkelt met als doel het leven van mensen met kanker en andere ernstige ziekten te verbeteren. Het bedrijf is gevestigd in Denemarken, de Verenigde Staten Japan, en in Nederland op het Utrecht Science Park. In deze vestiging vindt top wetenschappelijk onderzoek plaats, waar zo’n 650 medewerkers werken aan de medi…
Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chair…
Sign in to search the full transcript archive, filter by topic, and access every quote from Jan van de Winkel.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans